A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding bevacizumab to first-line chemotherapy for patients with ovarian cancer, ...

Adding bevacizumab to the combination therapy of carboplatin and paclitaxel significantly improved progression-free survival (PFS) in patients with epithelial ovarian cancer (EOC) but not overall ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding bevacizumab to first-line chemotherapy for patients with ovarian cancer, ...

High-risk advanced ovarian cancer patients showed marginal survival benefit with bevacizumab added to first-line chemotherapy. Patients without high-risk characteristics did not show significant ...

ZURICH, May 21 (Reuters) - Swiss drugmaker Roche said it would report strong results with its top-selling cancer drug Avastin in ovarian cancer and reiterated the new use could add another 1 billion ...

ZURICH, Aug 6 (Reuters) - Roche said on Wednesday that European regulators approved its drug Avastin as a treatment for women with ovarian cancer that is resistant to platinum-containing chemotherapy.